Tagcancer risk

What is the cancer risk with MS Disease-modifying treatments?

This question comes up time and again with MS treatments and probably is one of the most important negative selection choices secondary to PML for DMTs in MS. Every time a new drug is presented to the clinical community, the cancer stats are heavily scrutinised. For example, with ocrelizumab the greater number of breast cancers in the treated arm versus placebo impacted on who ultimately received...

Translate

Categories

Recent Posts

Recent Comments

Archives